Advertisement
Correspondence| Volume 20, ISSUE 4, P367-368, October 2011

Download started.

Ok

Severe postpartum haemorrhage treated with recombinant activated Factor VII in 80 Czech patients: analysis of the UniSeven registry

Published:September 12, 2011DOI:https://doi.org/10.1016/j.ijoa.2011.07.008
Severe postpartum haemorrhage treated with recombinant activated Factor VII in 80 Czech patients: analysis of the UniSeven registry
Previous ArticleEpidural catheter migration during labor: a comparison between standard and Epi-Guard fixation
Next ArticleManagement of a parturient with TAR syndrome during caesarean section and the use of thromboelastography
      Postpartum haemorrhage (PPH), most commonly caused by uterine atony, is a major cause of maternal mortality in developed countries.
      • Zhang W.H.
      • Alexander S.
      • Bouvier-Colle M.H.
      • Macfarlane A.
      MOMS-B Group
      Incidence of severe pre-eclampsia, postpartum haemorrhage and sepsis as a surrogate marker for severe maternal morbidity in a European population-based study: the MOMS-B survey.
      BJOG. 2005; 112: 89-96
      , 
      • Khan K.S.
      • Wojdyla D.
      • Say L.
      • Gülmezoglu A.M.
      • Van Look P.F.
      WHO analysis of causes of maternal death: a systematic review.
      Lancet. 2006; 367: 1066-1074
      , 
      • Alfirevic Z.
      • Elbourne D.
      • Pavord S.
      • et al.
      Use of recombinant activated factor VII in primary postpartum hemorrhage: the Northern European registry 2000–2004.
      Obstet Gynecol. 2007; 110: 1270-1278
      , 
      • Duffy M.R.
      Guidelines for use of recombinant factor VIIa in life-threatening post-partum haemorrhage.
      Int J Obstet Anesth. 2007; 16: 299-300
      , 
      • Barillari G.
      • Frigo M.G.
      • Casarotto M.
      • et al.
      Use of recombinant activated factor VII in severe post-partum haemorrhage: data from the Italian Registry: a multicentric observational retrospective study.
      Thromb Res. 2009; 124: e41-e47
      , 
      • Franchini M.
      • Franchi M.
      • Bergamini V.
      • Salvagno G.L.
      • Montagnana M.
      • Lippi G.
      A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage.
      Semin Thromb Hemost. 2008; 34: 104-112
      Each year, between 5 and 10 women die from PPH in the Czech Republic; 10 times as many survive life-threatening haemorrhage, but these women may suffer lifelong complications.
      • Feyereisl J.
      Závažné postpartální hemoragie a doporučený postup k léčbě [Severe postpartal hemorrhages – treatment guideline].
      Ceska Gynek. 2008; 73: 375-376
      Recombinant activated factor VII (rFVIIa; Novo-Seven®, Novo Nordisk, Begsvaerd, Denmark) has been frequently used ‘off-label’ to treat haemorrhage in patients without primary defects of the coagulation system, such as women with PPH.
      • Segal S.
      • Shemesh I.Y.
      • Blumental R.
      • et al.
      The use of recombinant factor VIIa in severe postpartum hemorrhage.
      Acta Obstet Gynecol Scand. 2004; 83: 771-772
      , 
      • Ahonen J.
      • Jokela R.
      Recombinant factor VIIa for life-threatening post-partum haemorrhage.
      Br J Anaesth. 2005; 94: 592-595
      , 
      • Hossain N.
      • Shamsi T.
      • Haider S.
      • et al.
      Use of recombinant activated factor VII for massive postpartum hemorrhage.
      Acta Obstet Gynecol Scand. 2007; 86: 1200-1206
      , 
      • Haynes J.
      • Laffan M.
      • Plaat F.
      Use of recombinant activated factor VII in massive obstetric haemorrhage.
      Int J Obstet Anesth. 2007; 16: 40-49
      , 
      • Welsh A.
      • McLintock C.
      • Gatt S.
      • Somerset D.
      • Popham P.
      • Ogle R.
      Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage.
      Aust N Z J Obstet Gynaecol. 2008; 48: 12-16
      Guidelines for rFVIIa use in PPH have appeared in several countries,
      • Duffy M.R.
      Guidelines for use of recombinant factor VIIa in life-threatening post-partum haemorrhage.
      Int J Obstet Anesth. 2007; 16: 299-300
      , 
      • Feyereisl J.
      Závažné postpartální hemoragie a doporučený postup k léčbě [Severe postpartal hemorrhages – treatment guideline].
      Ceska Gynek. 2008; 73: 375-376
      , 
      • Welsh A.
      • McLintock C.
      • Gatt S.
      • Somerset D.
      • Popham P.
      • Ogle R.
      Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage.
      Aust N Z J Obstet Gynaecol. 2008; 48: 12-16
      , 
      • Binder T.
      • Cvachovec K.
      • Černý V.
      • et al.
      Diagnostika a léčba akutního peripartálního život ohrožujícího krvácení – doporučený postup [Diagnostics and treatment of acute peripartal life-threatening bleeding – guideline].
      Ceska Gynek. 2008; 73: 377-379
      and clinical registry data supporting its use have been published from Northern Europe
      • Alfirevic Z.
      • Elbourne D.
      • Pavord S.
      • et al.
      Use of recombinant activated factor VII in primary postpartum hemorrhage: the Northern European registry 2000–2004.
      Obstet Gynecol. 2007; 110: 1270-1278
      and Italy.
      • Barillari G.
      • Frigo M.G.
      • Casarotto M.
      • et al.
      Use of recombinant activated factor VII in severe post-partum haemorrhage: data from the Italian Registry: a multicentric observational retrospective study.
      Thromb Res. 2009; 124: e41-e47
      The UniSeven registry was established in 2004 to collect data on rFVIIa administration in non-haemophiliac patients from the Czech Republic, Slovakia, Slovenia and Hungary. We analysed cases of life-threatening PPH reported in Czech patients included in this registry in order to assess the efficacy and safety of rFVIIa in PPH, and to investigate whether early administration of rFVIIa might prevent hysterectomy and thus preserve fertility.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to International Journal of Obstetric Anesthesia
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Zhang W.H.
        • Alexander S.
        • Bouvier-Colle M.H.
        • Macfarlane A.
        • MOMS-B Group
        Incidence of severe pre-eclampsia, postpartum haemorrhage and sepsis as a surrogate marker for severe maternal morbidity in a European population-based study: the MOMS-B survey.
        BJOG. 2005; 112: 89-96
        View in Article
        • Khan K.S.
        • Wojdyla D.
        • Say L.
        • Gülmezoglu A.M.
        • Van Look P.F.
        WHO analysis of causes of maternal death: a systematic review.
        Lancet. 2006; 367: 1066-1074
        View in Article
        • Alfirevic Z.
        • Elbourne D.
        • Pavord S.
        • et al.
        Use of recombinant activated factor VII in primary postpartum hemorrhage: the Northern European registry 2000–2004.
        Obstet Gynecol. 2007; 110: 1270-1278
        View in Article
        • Duffy M.R.
        Guidelines for use of recombinant factor VIIa in life-threatening post-partum haemorrhage.
        Int J Obstet Anesth. 2007; 16: 299-300
        View in Article
        • Barillari G.
        • Frigo M.G.
        • Casarotto M.
        • et al.
        Use of recombinant activated factor VII in severe post-partum haemorrhage: data from the Italian Registry: a multicentric observational retrospective study.
        Thromb Res. 2009; 124: e41-e47
        View in Article
        • Franchini M.
        • Franchi M.
        • Bergamini V.
        • Salvagno G.L.
        • Montagnana M.
        • Lippi G.
        A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage.
        Semin Thromb Hemost. 2008; 34: 104-112
        View in Article
        • Feyereisl J.
        Závažné postpartální hemoragie a doporučený postup k léčbě [Severe postpartal hemorrhages – treatment guideline].
        Ceska Gynek. 2008; 73: 375-376
        View in Article
        • Segal S.
        • Shemesh I.Y.
        • Blumental R.
        • et al.
        The use of recombinant factor VIIa in severe postpartum hemorrhage.
        Acta Obstet Gynecol Scand. 2004; 83: 771-772
        View in Article
        • Ahonen J.
        • Jokela R.
        Recombinant factor VIIa for life-threatening post-partum haemorrhage.
        Br J Anaesth. 2005; 94: 592-595
        View in Article
        • Hossain N.
        • Shamsi T.
        • Haider S.
        • et al.
        Use of recombinant activated factor VII for massive postpartum hemorrhage.
        Acta Obstet Gynecol Scand. 2007; 86: 1200-1206
        View in Article
        • Haynes J.
        • Laffan M.
        • Plaat F.
        Use of recombinant activated factor VII in massive obstetric haemorrhage.
        Int J Obstet Anesth. 2007; 16: 40-49
        View in Article
        • Welsh A.
        • McLintock C.
        • Gatt S.
        • Somerset D.
        • Popham P.
        • Ogle R.
        Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage.
        Aust N Z J Obstet Gynaecol. 2008; 48: 12-16
        View in Article
        • Binder T.
        • Cvachovec K.
        • Černý V.
        • et al.
        Diagnostika a léčba akutního peripartálního život ohrožujícího krvácení – doporučený postup [Diagnostics and treatment of acute peripartal life-threatening bleeding – guideline].
        Ceska Gynek. 2008; 73: 377-379
        View in Article
        • Rossaint R.
        • Spahn D.R.
        Trauma: bleeding, coagulopathy and blood component transfusion.
        in: Vincent J.L. Yearbook of Intensive Care and Emergency Medicine. Springer-Verlag, New York2006: 255-264
        View in Article

      Article info

      Publication history

      Published online: September 12, 2011
      Accepted: July 4, 2011

      Identification

      DOI: https://doi.org/10.1016/j.ijoa.2011.07.008

      Copyright

      © 2011 Elsevier Ltd. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX